Latest Breaking News On - Corporate communications investors - Page 2 : comparemela.com

Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023

Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomPaul hughesSilviu itescuSteve dabkowskiMarrow transplant clinical trials networkAustralian securities exchangeCorporate communications investorsPharmaceuticals coProgram in chronic heart failureNational institutes of healthMesoblast limited nasdaqProgram in pediatric congenital heart diseaseChief executive silviu itescuRare pediatric diseaseHost disease

Appendix 4C Quarterly Activity Report for Quarter Ended

NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for.

United statesUnited kingdomSteve dabkowskiSilviu itescuPaul hughesMarrow transplant clinical trials networkNational institutes of healthProgram in chronic heart failureAustralian securities exchangeCorporate communications investorsPharmaceuticals coMesoblast limited nasdaqProgram in pediatric congenital heart diseaseChief executive silviu itescuRare pediatric diseaseHost disease

United States Food & Drug Administration (FDA) Grants

FDA GRANTS MESOBLAST RARE PEDIATRIC DISEASE DESIGNATION FOR REVASCOR® (REXLEMESTROCEL-L) IN CHILDREN WITH CONGENITAL HEART DISEASE.

United statesSilviu itescuSteve dabkowskiPaul hughesMesoblast limited nasdaqDrug administrationJournal of the american college cardiologyCorporate communications investorsAustralian securities exchangeRevascor increases size of left heart chamberMesoblast the companyLeft heart chamberImproves surgical outcomesHypoplastic left heart syndromeResults publishedCardiovascular surgery

United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease

United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesPaul hughesSteve dabkowskiSilviu itescuMesoblast limited nasdaqCorporate communications investorsJournal of the american college cardiologyDrug administrationAustralian securities exchangeMesoblast the companyRevascor increases size of left heart chamberLeft heart chamberImproves surgical outcomesHypoplastic left heart syndromeResults publishedCardiovascular surgery

Mesoblast Files for Orphan Drug and Pediatric Rare Disease

NEW YORK, Nov. 26, 2023 (GLOBE NEWSWIRE) Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory.

United statesSteve dabkowskiPaul hughesMesoblast the companyMesoblast limited nasdaqAustralian securities exchangeJournal of the american college cardiologyCorporate communications investorsDrug administrationUnited states foodCardiovascular surgery openMesoblast limitedPatients with heartAmerican collegePrivate securities litigation reform actAustralian stock exchange msb ax